Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.75 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.73 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.73 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.73 |
| ▸ | TNF | P01375 | 1/20 | 0.73 |
| ▸ | IL1B | P01584 | 1/20 | 0.73 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009197 | 1.00 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL2032577 | 1.00 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL2037171 | 1.00 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19611896 | 0.93 | CRBN (0.65) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL18270885 | 0.93 | CRBN (0.65) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19611895 | 0.93 | CRBN (0.65) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL26141973 | 0.88 | CRBN (0.58) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL25571498 | 0.87 | CRBN (0.56) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL25031818 | 0.86 | CRBN (0.77) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL1097880 | 0.86 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964354-B2 | Use of micro-RNA as a biomarker of immunomodulatory drug activity | CELGENE CORPORATION (US) | 2011-06-21 | — | — | US | claimed |
| EP-2235213-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION (US) | 2010-10-06 | — | — | EP | claimed |
| WO-2009085234-A9 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION (US) | 2010-08-12 | — | — | WO | claimed |
| WO-2009085234-A2 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | SIGNAL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090176237-A1 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION | 2009-07-09 | — | — | US | claimed |
| US-20090163548-A1 | Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | CELGENE CORPORATION | 2009-06-25 | — | — | US | claimed |
| US-20090155207-A1 | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders | CELGENE CORPORATION | 2009-06-18 | — | — | US | claimed |
| WO-2009073146-A2 | USE OF IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF TRANSVERSE MYELITIS, MULTIPLE SCLEROSIS, AND OTHER DISORDERS | CELGENE CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090087407-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA USING 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-METHYLISOINDOLINE | CELGENE CORPORATION | 2009-04-02 | — | — | US | claimed |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2008-11-20 | — | — | US | claimed |
| US-20070244078-A1 | Methods for Treatment, Modification and Management of Pain Using 1-Oxo-2-(2,6-Dioxopiperidin-3-yl)-4-Methylisoindoline | CELGENE CORPORATION | 2007-10-18 | — | — | US | claimed |
| EP-1814543-A2 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF PARASITIC DISEASES | CELGENE CORPORATION (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060199843-A1 | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline | CELGENE CORPORATION | 2006-09-07 | — | — | US | claimed |
| US-20060154880-A1 | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases | HENSEL JENNIFER L | 2006-07-13 | — | — | US | claimed |
| WO-2006053160-A2 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF PARASITIC DISEASES | CELGENE CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1064277-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | CELGENE CORP (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | claimed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | claimed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244078-A1 | Methods for Treatment, Modification and Management of Pain Using 1-Oxo-2-(2,6-Dioxopiperidin-3-yl)-4-Methylisoindoline | TPMT, IL2, IL6 | CRBN 4326/4885IKZF3 2262/4885DDB1 2051/4885 |
| US-20090155207-A1 | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders | IL2, MYT1, THPO | CRBN 1748/4885IKZF3 92/4885DDB1 816/4885 |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | CRBN 4056/4885IKZF3 275/4885DDB1 621/4885 |
| US-20060154880-A1 | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases | IL2, ICOS, IL5 | CRBN 3154/4885IKZF3 92/4885DDB1 4396/4885 |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | TNF, IL1A, IL1B | CRBN 4134/4885IKZF3 275/4885DDB1 733/4885 |
| US-20090087407-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA USING 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-METHYLISOINDOLINE | MMP1, MMP13, SSB | CRBN 4824/4885IKZF3 1302/4885DDB1 1450/4885 |
| US-20060199843-A1 | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline | VEGFA, IL2, HDGF | CRBN 1229/4885IKZF3 1139/4885DDB1 971/4885 |
| US-20090163548-A1 | Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | MCL1, BCL6B, BCL6 | CRBN 563/4885IKZF3 356/4885DDB1 2644/4885 |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | TNF, IL1A, IL1B | CRBN 4134/4885IKZF3 275/4885DDB1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.